NDC 0006-3083 – Keytruda Qlex
Pembrolizumab 165 mg/mL; Berahyaluronidase Alfa 2000 U/mL · Injection, Solution · Subcutaneous
Product NDC0006-3083
Product details
- Brand name
- Keytruda Qlex
- Generic name
- Pembrolizumab and berahyaluronidase alfa-pmph
- Labeler
- Merck Sharp & Dohme LLC
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Marketing category
- BLA · BLA761467
- Marketed since
- September 19, 2025
- Listing expires
- December 31, 2027
- Pharmacologic class
- Endoglycosidase; Programmed Death Receptor-1 Blocking Antibody
Active ingredients
- Pembrolizumab 165 mg/mL
- Berahyaluronidase Alfa 2000 U/mL
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 0006-3083-01 | 1 VIAL in 1 CARTON (0006-3083-01) / 2.4 mL in 1 VIAL (0006-3083-99) | Sep 19, 2025 |
Other Keytruda Qlex products
- 0006-5083 Pembrolizumab 165 mg/mL; Berahyaluronidase Alfa 2000 U/mL · Injection, Solution · Merck Sharp & Dohme LLC